DUX4 抗体 (AA 53-120) (Biotin)
Quick Overview for DUX4 抗体 (AA 53-120) (Biotin) (ABIN1699985)
抗原
See all DUX4 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 53-120
-
预测反应
- Human
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic peptide derived from human DUX4
-
亚型
- IgG
-
-
anti-Double Homeobox 4 (DUX4) (C-Term) antibody
DUX4 适用: 人 WB, IHC, IF, ICC 宿主: 小鼠 Monoclonal P2B1 unconjugated
anti-Double Homeobox 4 (DUX4) (AA 217-402) antibodyDUX4 适用: 人 WB, IHC, ELISA 宿主: 兔 Polyclonal unconjugated
anti-Double Homeobox 4 (DUX4) (C-Term) antibody (Atto 390)DUX4 适用: 人 WB, IHC, IF, ICC 宿主: 小鼠 Monoclonal P2B1 Atto 390
anti-Double Homeobox 4 (DUX4) (C-Term) antibody (HRP)DUX4 适用: 人 WB, IHC, IF, ICC 宿主: 小鼠 Monoclonal P2B1 HRP
anti-Double Homeobox 4 (DUX4) (C-Term) antibody (FITC)DUX4 适用: 人 WB, IHC, IF, ICC 宿主: 小鼠 Monoclonal P2B1 FITC
anti-Double Homeobox 4 (DUX4) (C-Term) antibody (Biotin)DUX4 适用: 人 WB, IHC, IF, ICC 宿主: 小鼠 Monoclonal P2B1 Biotin
anti-Double Homeobox 4 (DUX4) (C-Term) antibody (PE)DUX4 适用: 人 WB, IHC, IF, ICC 宿主: 小鼠 Monoclonal P2B1 PE
anti-Double Homeobox 4 (DUX4) (C-Term) antibody (PerCP)DUX4 适用: 人 WB, IHC, IF, ICC 宿主: 小鼠 Monoclonal P2B1 PerCP
anti-Double Homeobox 4 (DUX4) (C-Term) antibody (APC)DUX4 适用: 人 WB, IHC, IF, ICC 宿主: 小鼠 Monoclonal P2B1 APC
anti-Double Homeobox 4 (DUX4) (C-Term) antibody (Atto 594)DUX4 适用: 人 WB, IHC, IF, ICC 宿主: 小鼠 Monoclonal P2B1 Atto 594
-
-
应用备注
-
WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500 -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- Store at -20°C for 12 months.
-
有效期
- 12 months
-
-
- DUX4 (Double Homeobox 4 (DUX4))
-
别名
- DUX4
-
背景
-
Synonyms: Double homeobox protein 10, Double homeobox protein 4, Double homeobox protein 4/10, DUX10, DUX4_HUMAN.
Background: DUX4 is a homeodomain protein with a similar protein sequence to Pax3 and Pax7. Defects in DUX4 may be the cause of facioscapulohumeral muscular dystrophy (FSHD). FSHD is characterized by weakness of the muscles of the face, upper-arm and shoulder girdle. Severity is highly variable. Weakness is slowly progressive and about 20 % of affected individuals eventually require a wheelchair. Approximately 70-90 % of individuals have inherited the disease-causing deletion from a parent, and approximately 10-30 % of affected individuals have FSHD as the result of a de novo deletion. Offsprings of an affected individual have a 50 % chance of inheriting the deletion.
抗原
-
